SEC Form 4 · accession 0001209191-17-041635
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Jun 21, 2017
Accepted (ET)
Jun 23, 2017 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 21, 2017 | M | 5,157 | $96.87 | A | 127,668 | D | |
| Common Stock | Jun 21, 2017 | S | 5,157 | $132.87 | D | 122,511 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $96.87 | Jun 21, 2017 | M | 5,157 | D | — | Jul 14, 2024 | Common Stock | 5,157 | 8,594 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 7/15/2014.